Use of sildenafil citrate for treatment of erec-tile dysfunction of various etiology


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Erectile dysfunction is closely linked to the general state of both physical and psychological wellness. Among the major risk factors are heart disease, arterial hypertension, diabetes, hyperlipidemia, as well as sedentary lifestyle, smoking and alcohol abuse. Also, the disease is more frequently found in men undergoing radiation therapy or surgery for prostate cancer. Psychological correlates include anxiety, depression and irritability. Despite a higher prevalence among older men, erectile dysfunction is not considered an inevitable part of aging. Due to polyetiology of the disease, sildenafil is regarded as the gold standard of treatment, and new high quality generic drugs are marketed. The article covers the use of sildenafil in patients with diseases of the cardiovascular system, diabetes, hypogonadism. Effectiveness of sildenafil in patients on chronic hemodialysis as well as in patients undergoing radical prostatectomy is discussed. The issue of addiction to sildenafil is outlined.

Full Text

Restricted Access

About the authors

E. A. Efremov

SRI of Urology n.a. N.A. Lopatkin - a branch of FSBI “FMRC n.a. P. A. Herzen” of the Minzdrav of Russia

Department of Andrology and Human Reproduction

E. V. Kasatonova

SRI of Urology n.a. N.A. Lopatkin - a branch of FSBI “FMRC n.a. P. A. Herzen” of the Minzdrav of Russia

Email: kasatonova@yandex.ru
Research Fellow of Department of Andrology and Human Reproduction

Ja. I. Melnik

SRI of Urology n.a. N.A. Lopatkin - a branch of FSBI “FMRC n.a. P. A. Herzen” of the Minzdrav of Russia

Department of Andrology and Human Reproduction

References

  1. Prins J., Blanker M.H., Bohnen A.M., Thomas S., Bosch J.L.H.R. Prevalence of erectile dysfunction: a systematic review of population- based studies. Int. J. Impot. Res. 2002;14:422-432.
  2. Пушкарь Д.Ю., Камалов А.А., Аль-Шукри С.Х., Еркович А.А., Коган М.И., Павлов В.Н., Журавлев В.Н., Берников А.Н. Эпидемиологическое исследование распространенности эректильной дисфункции в Российской Федерации. Урология. 2012;6:5-9.
  3. Boolell M., Allen M.J., Ballard S.A., Gepi-Attee S., Muirhead G.J., Naylor A.M., Osterloh I.H., Gingell C. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int. J. Impot. 1996;8(2):47-52.
  4. Jackson G., Boon N., Eardley I., Kirby M., Dean J., Hackett G., Montorsi P., Montorsi F., Vlachopoulos C., Kloner R., Sharlip I., Miner M. Erectile dysfunction and coronary artery disease prediction: evidence-based guidance and consensus. Int. J. Clin. Pract. 2010;64(7):848-857.
  5. Guazzi M., Tumminello G., DiMarco F., Guazzi M.D. Influences of Sildenafil on lung function and hemodynamics in patients with chronic heart failure. Clin. Pharmacol. Ther. 2004;76:371-378.
  6. Lewis G.D., Lachmann J., Camuso J., Lepore J.J., Shin J., Martinovic M.E., Systrom D.M., Bloch K.D., Semigran M.J. Sildenafil improves exercise hemodynamics and oxygen uptake in patients wth systolic heart failure. Circulation. 2007;115:59-66
  7. Shabsigh R., Perelman M., Lue T.F., Broderick G.A., Lockhardt D. Men’s health issues: prevalence and correlates of erectile dysfunction. J. Urol. 2005;174:662-667.
  8. Goldstein I., Lue T.F., Padma-Nathan H., Rosen R.C., Steers W.D., Wicker P.A. Oral sildenafil in the treatment of erectile dysfunction. N. Engl. J. Med. 1998;338:1397-1404.
  9. Rendell M.S., Rajfer J., Wicker P.A., Smith M.D. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA. 1999;281(5):421-426.
  10. Jonas U. The history of erectile dysfunction management. Int. J. Impot. Res. 2001;13(3):3-7.
  11. Escrig A., Gonzalez-Mora J.L., Mas M. Nitric oxide release in penile corpora cavernosa in a rat model of erection. J. Physiol. 1999;516(Pt. 1):261-269.
  12. Guay A.T., Perez J.B., Jacobson J., Newton R.A. Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors. J. Androl. 2001;22:793-797.
  13. Shabsigh R., Kaufman J.M., Steidle C., Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J. Urol. 2008;179(5):97-102.
  14. Zippe C.D., Jhaveri F.M., Klein E.A., Kedia S., Pasqualotto F.F., Kedia A., Agarwal A., Montague D.K., Lakin M.M. Role of Viagra after radical prostatectomy. Urology. 2000;55(2):241-245.
  15. Shimizu T., Hisasue S., Sato Y., Kato R., Kobayashi K., Tsukamoto T. Erectile dysfunction following nerve-sparing radical retropubic prostatectomy and its treatment with sildenafil. Int. J. Urol. 2005;12(6):552-557.
  16. Padma-Nathan H., McCullough A.R., Levine L.A., Lipshultz L.I., Siegel R., Montorsi F., Giuliano F., Brock G.; Study Group. Randomized, doubleblind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int. J. Impot. Res. 2008;20(5):479-486.
  17. Tutolo M., Briganti A., Suardi N., Gallina A., Abdollah F., Capitanio U., Bianchi M., Passoni N., Nini A., Fossati N., Rigatti P., Montorsi F. Optimizing postoperative sexual function after radical prostatectomy. Ther. Adv. Urol. 2012;4(6):347-365.
  18. Goldstein I., Lurie A.L., Lubisich J.P. Bicycle riding, perineal trauma, and erectile dysfunction: data and solutions. Curr. Urol. Rep. 2007;8(6):491-497.
  19. Harwood P.J., Grotz M., Eardley I., Giannoudis P.V. Erectile dysfunction after fracture of the pelvis. J. Bone Joint. Surg. Br. 2005;87(3):281-290.
  20. Ghafari A., Farshid B., Afshari A.T., Sepehrvand N., Rikhtegar E., Ghasemi K., Hatami S. Sildenafil citrate can improve erectile dysfunction among chronic hemodialysis patients. Indian J. Nephrol. 2010;20(3):142-145.
  21. Seibel I., Poli De Figueiredo C.E., Teloken C., Moraes J.F. Efficacy of oral sildenafil in hemodialysis patients with erectile dysfunction. J. Am. Soc. Nephrol. 2002;13(11);2770-2775.
  22. Mohamed E.A., MacDowall P., Coward R.A. Timing of sildenafil therapy in dialysis patients-lessons following an episode of hypotension. Nephrol. Dial. Transplant. 2000;15(6):926-927.
  23. Silver B., McCarthy S., Lu M., Mitsias P., Russman A.N., Katramados A., Morris D.C., Lewandowski C.A., Chopp M. Sildenafil treatment ofsubacute ischemic stroke: a safety study at 25-mg daily for 2 weeks. J. Stroke Cerebrovasc Dis. 2009;18(5):381-383.
  24. Gheita T.A., Ammar H., Kenawy S.A. Potential effect of Sildenafil beyond pulmonary hypertension in a patient with diffuse systemic sclerosis and cryoglobulinemic vasculitis. Springerplus. 2014;26(3):559.
  25. Fletcher E.C., Martin R.J. Sexual dysfunction and erectile impotence in chronic obstructive pulmonary disease. Chest. 1982;81(4):413-421.
  26. Blanco I., Gimeno E., Munoz P.A., Pizarro S., Gistau C., Rodriguez- Roisin R., Roca J., Barbera J.A. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am. J. Respir. Crit. Care Med. 2010;181(3):270-278.
  27. Simsek I., Aslan G., Akarsu M., Koseoglu H., Esen A. Assessment of sexual functions in patients with chronic liver disease. Int. J. Impot. Res. 2005;17(4):343-345.
  28. Clemmesen J.O., Giraldi A., Ott P., Dalhoff K., Hansen B.A., Larsen F.S. Sildenafil does not influence hepatic venous pressure gradient in patients with cirrhosis. WJG. 2008;40(14):6208-6212.
  29. Seidman S.N., Roose S.P., Menza M.A., Shabsigh R., Rosen R.C. Treatment of erectile dysfunction in men with depressive symptoms: results of a placebo-controlled trial with sildenafil citrate. Am. J. Psychiatry. 2001;158:1623-1630.
  30. Zajecka J., Mitchell S., Fawcett J. Treatment-emergent changes in sexual function with selective serotonin reuptake inhibitors as measured with the Rush Sexual Inventory. Psychopharmacol Bull. 1997;33:755-760.
  31. Giuliano F., Jackson G., Montorsi F., Martin-Morales A., Raillard P. Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database. Int. J. Clin. Pract. 2010;64(2):240- 255.
  32. McMurray J.G., Feldman R.A., Auerbach S.M. Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction. Ther. Clin. Risk Manag. 2007;3:975-981.
  33. Christiansen E., Guirguis W.R., Cox D., Osterloh I.H.; Sildenafil Multicentre Study Group. Long-term efficacy and safety of oral Viagra (sildenafil citrate) in men with erectile dysfunction and the effect of randomised treatment withdrawal. Int. J. Impot. Res. 2000;12(3):177-182.
  34. Инструкция по медицинскому применению препарата Динамико. http://www.rlsnet.ru/tn_index_id_47499.htm.
  35. Камалов А.А., Осмоловский Б.Е., Охоботов Д.А., Ходырева Л.А., Тахирзаде Т.Б., Тахирзаде А.М., Геворкян А.Р. Комбинированное лечение больных эректильной дисфункцией, страдающих расстройствами мочеиспускания. Урология. 2013;3:29-33.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies